1,101 results

#184570-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-LiLac (#184570). In addition to the viral particles, you will also receive purified pAAV-CAG-LiLac plasmid DNA. CAG-driven expression of lactate sensor LiLac. These AAV preparations are suitable purity for injection into animals.

Gary Yellen

Koveal et al Nat Commun. 2022 May 25;13(1):2919. doi:

Feb. 6, 2026

Academic Institutions and Nonprofits only

#92207-AAV1

Ready-to-use AAV1 particles produced from TRE-ChrimsonR-mCherry (#92207). In addition to the viral particles, you will also receive purified TRE-ChrimsonR-mCherry plasmid DNA. TRE-driven ChrimsonR-mCherry expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Alice Ting

Wang et al Nat Biotechnol. 2017 Jun 26. doi: 10.103

Nov. 13, 2025

Academic Institutions and Nonprofits only

#104052-AAVPHP.V1

Ready-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

July 24, 2020

Academic Institutions and Nonprofits only

#230804-AAV1

Ready-to-use AAV1 particles produced from AiP20168 - pAAV-AiE2575m-minBG-iCre-WPRE3-BGHpA (#230804). In addition to the viral particles, you will also receive purified AiP20168 - pAAV-AiE2575m-minBG-iCre-WPRE3-BGHpA plasmid DNA. minBG-driven expression of iCre in specific populations of brain cells. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Bosiljka Tasic

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Feb. 9, 2026

Academic Institutions and Nonprofits only

#83899-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

June 1, 2020

Academic Institutions and Nonprofits only

#105542-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.CB7.CI.eGFP.WPRE.rBG (#105542). In addition to the viral particles, you will also receive purified pENN.AAV.CB7.CI.eGFP.WPRE.rBG plasmid DNA. CB7-driven eGFP. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

May 8, 2018

Academic Institutions and Nonprofits only

#18916-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-rev-ChR2(H134R)-mCherry (#18916). In addition to the viral particles, you will also receive purified AAV-FLEX-rev-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, cre-dependent, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al J Neurosci. 2008 Jul 9. 28(28):7025-30.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#205997-AAV9

Ready-to-use AAV9 particles produced from pAAV_hSyn_WiChR_TS_mScarlet_ER (#205997). In addition to the viral particles, you will also receive purified pAAV_hSyn_WiChR_TS_mScarlet_ER plasmid DNA. hSyn-driven K+ selective channelrhodopsin for optogenetic inhibition of neurons. These AAV preparations are suitable purity for injection into animals.

Peter Hegemann, Johannes Vierock

Vierock et al Sci Adv. 2022 Nov 16:eadd7729.

July 30, 2025

Academic Institutions and Nonprofits only

#218876-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-iGABASnFR2(no bind)-WPRE (#218876). In addition to the viral particles, you will also receive purified pGP-AAV-syn-iGABASnFR2(no bind)-WPRE plasmid DNA. Syn-driven expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#176756-AAV1

Ready-to-use AAV1 particles produced from AAV-EF1a-jGCaMP8f-WPRE (#176756). In addition to the viral particles, you will also receive purified AAV-EF1a-jGCaMP8f-WPRE plasmid DNA. EF1a-driven expression of calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#140135-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Sept. 15, 2021

Academic Institutions and Nonprofits only

#176748-AAV9

Ready-to-use AAV9 particles produced from AAV-Syn-H2B-jGCaMP8m-WPRE (#176748). In addition to the viral particles, you will also receive purified AAV-Syn-H2B-jGCaMP8m-WPRE plasmid DNA. Syn-driven expression of histone H2B fused to calcium sensor GCaMP8m. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#98930-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 (#98930). In addition to the viral particles, you will also receive purified pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 plasmid DNA. GFAP-driven glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

March 15, 2018

Academic Institutions and Nonprofits only

#179255-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-CAG-jGCaMP8m-WPRE (#179255). In addition to the viral particles, you will also receive purified AAV-CAG-jGCaMP8m-WPRE plasmid DNA. CAG-driven expression of calcium sensor GCaMP8m. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

March 18, 2024

Academic Institutions and Nonprofits only

#167572-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-Ribo-jGCaMP8s (#167572). In addition to the viral particles, you will also receive purified AAV-hSyn-Ribo-jGCaMP8s plasmid DNA. Synapsin-driven neuronal expression of soma-targeted (RL-10, ribosomal tag) jGCaMP8s. These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

Dec. 18, 2024

Academic Institutions and Nonprofits only

#228902-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine (#228902). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine plasmid DNA. CAG-driven, Cre dependent expression of a peripherally restricted DREADD. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Kang et al Cell. 2024 Dec 26;187(26):7433-7449.e20.

Oct. 8, 2025

Academic Institutions and Nonprofits only

#100040-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn1.Twitch2B.WPRE.SV40 (#100040). In addition to the viral particles, you will also receive purified pAAV.hSyn1.Twitch2B.WPRE.SV40 plasmid DNA. Synapsin-driven expression of (FRET)-based calcium biosensor Twitch2B. These AAV preparations are suitable purity for injection into animals.

Oliver Griesbeck

Thestrup et al Nat Methods. 2014 Jan 5. doi: 10.1038/nm

March 8, 2018

Academic Institutions and Nonprofits only

#172923-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-jGCaMP8f-P2A-mRuby3 (#172923). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-jGCaMP8f-P2A-mRuby3 plasmid DNA. hSyn-driven expression of jGCaMP8f in axons with cytosolic expression of mRuby3. These AAV preparations are suitable purity for injection into animals.

GENIE Project

June 8, 2023

Academic Institutions and Nonprofits only

#157970-AAV.A12.T

Ready-to-use AAV44.9(E531D) in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#213833-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#135633-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#153286-AAV2

Ready-to-use AAV2 particles produced from pAAV-hsyn-GRAB_Ado1.0med (#153286). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_Ado1.0med plasmid DNA. Synapsin-driven expression of GRAB_Ado1.0med adenosine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Wu et al Proc Natl Acad Sci U S A. 2023 Apr 4;120

Nov. 13, 2025

Academic Institutions and Nonprofits only

#100832-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.CaMPARI.WPRE.SV40 (#100832). In addition to the viral particles, you will also receive purified pAAV.hSyn.CaMPARI.WPRE.SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator. These AAV preparations are suitable purity for injection into animals.

Loren Looger, Eric Schreiter

Fosque et al Science. 2015 Feb 13;347(6223):755-60. d

April 6, 2018

Academic Institutions and Nonprofits only

#35512-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry (#35512). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin E123T/T159C mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Nov. 13, 2025

Academic Institutions and Nonprofits only

#135633-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#105547-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

May 4, 2018

Academic Institutions and Nonprofits only

#106176-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynapsin.SF-iGluSnFR.S72A (#106176). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.S72A plasmid DNA. hSynapsin driven SF-iGluSnFR.S72A, glutamate sensor. The S72A mutant has lower affinity for glutamate. Slower on-rate and faster off-rate. Enhanced temporal resolution and spatial resolution. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 25, 2019

Academic Institutions and Nonprofits only

#230884-AAV2

Ready-to-use AAV2 particles produced from AiP15646: pAAV-AiE1426m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN5646) (#230884). In addition to the viral particles, you will also receive purified AiP15646: pAAV-AiE1426m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN5646) plasmid DNA. minBG-driven expression of SYFP2 in cortical and striatal Sst-Chodl neurons. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 14, 2025

Academic Institutions and Nonprofits only

#214848-AAV2

Ready-to-use AAV2 particles produced from AiP13780: pAAV-AiE0743m_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN3780) (#214848). In addition to the viral particles, you will also receive purified AiP13780: pAAV-AiE0743m_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN3780) plasmid DNA. minBG-driven expression of iCre(R297T) in striatal cholinergic neurons. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 14, 2025

Academic Institutions and Nonprofits only

#173044-AAV2

Ready-to-use AAV2 particles produced from AAV-Camk2-NES-Twitch-GR (#173044). In addition to the viral particles, you will also receive purified AAV-Camk2-NES-Twitch-GR plasmid DNA. CamKII-driven expression of TnC-based calcium biosensor NES-Twitch-GR. These AAV preparations are suitable purity for injection into animals.

Yiyang Gong

Zhang et al Commun Biol. 2021 Jul 29;4(1):924. doi:

Nov. 13, 2025

Academic Institutions and Nonprofits only

#135635-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 29, 2021

Academic Institutions and Nonprofits only

#200778-AAV8

Ready-to-use AAV8 particles produced from AAV-∆Hapln1 (#200778). In addition to the viral particles, you will also receive purified AAV-∆Hapln1 plasmid DNA. Syn-driven, HAPLN1(delta40-154)-cfGFP expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#200777-AAV8

Ready-to-use AAV8 particles produced from AAV-HAPLN1 (#200777). In addition to the viral particles, you will also receive purified AAV-HAPLN1 plasmid DNA. Syn-driven, HAPLN1-cfGFP expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#200773-AAV8

Ready-to-use AAV8 particles produced from AAV-cfGFP (#200773). In addition to the viral particles, you will also receive purified AAV-cfGFP plasmid DNA. Syn-driven, cysteine-free GFP (cfGFP) expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#157970-AAV.A01.T

Ready-to-use AAV2 in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#121538-AAV2

Ready-to-use AAV2 particles produced from pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) (#121538). In addition to the viral particles, you will also receive purified pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) plasmid DNA. Synapsin-driven, HA-tagged hM4D(Gi) for neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Sept. 25, 2019

Academic Institutions and Nonprofits only

#105542-AAV8

Ready-to-use AAV8 particles produced from pENN.AAV.CB7.CI.eGFP.WPRE.rBG (#105542). In addition to the viral particles, you will also receive purified pENN.AAV.CB7.CI.eGFP.WPRE.rBG plasmid DNA. CB7-driven eGFP. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 25, 2018

Academic Institutions and Nonprofits only

#99130-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Sept. 18, 2019

Academic Institutions and Nonprofits only

#214862-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) (#214862). In addition to the viral particles, you will also receive purified AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) plasmid DNA. minBG-driven expression of iCre(R297T) in striatal medium spiny neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#100832-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSyn.CaMPARI.WPRE.SV40 (#100832). In addition to the viral particles, you will also receive purified pAAV.hSyn.CaMPARI.WPRE.SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator. These AAV preparations are suitable purity for injection into animals.

Loren Looger, Eric Schreiter

Fosque et al Science. 2015 Feb 13;347(6223):755-60. d

April 17, 2018

Academic Institutions and Nonprofits only

#105537-rh10

Ready-to-use AAV rh10 (similar to AAV10) particles produced from pENN.AAV.CMVs.Pl.Cre.rBG (#105537). In addition to the viral particles, you will also receive purified pENN.AAV.CMVs.Pl.Cre.rBG plasmid DNA. CMV-driven Cre. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 12, 2018

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#105321-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (#105321). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

July 12, 2019

Academic Institutions and Nonprofits only

#213939-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_GCaMP6f (#213939). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#162382-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE (#162382). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of the ultrafast calcium sensor GCaMP8f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Sept. 13, 2021

Academic Institutions and Nonprofits only

#105548-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.CMVs.TurboRFP.WPRE.RBG (#105548). In addition to the viral particles, you will also receive purified pENN.AAV.CMVs.TurboRFP.WPRE.RBG plasmid DNA. CMV-driven TurboRFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#198516-AAV1

Ready-to-use AAV1 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#213937-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_ChR2_mCherry (#213937). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only